Exposure to estrogenic endocrine disrupting chemicals (EDCs) during in utero development has been linked to the increasing incidence of disorders of sexual development. Hypospadias, the ectopic placement of the urethra on the ventral aspect of the penis, is one of the most common DSDs affecting men, and can also affect women by resulting in the misplacement of the urethra. This study aimed to comprehensively assess the resulting hypospadias phenotypes in male and female mice exposed in utero from embryonic day 9.5 to 19.5 to the potent estrogenic endocrine disruptor, diethylstilbestrol, at a high, clinically relevant dose, and a low, previously untested dose, administered via water. The anogenital distance of male pups was significantly reduced and hypospadias was observed in males at a high frequency. Females exhibited hypospadias and urethral-vaginal fistula. These results demonstrate the ability of an estrogen receptor agonist to disrupt sexual development in both male and female mice, even at a low dose, administered via drinking water.
Introduction
Endocrine disrupting chemicals (EDCs) have been linked to the increasing incidence of disorders of sexual development (DSDs) in humans [1] . This is due to their ability to interfere with hormonal pathways that are vital for early sexual development. EDCs that mimic estrogen are some of the most pervasive and damaging [2] . Estrogen receptors are expressed throughout the developing reproductive tract of males and females [3] , including the gonads and genital tubercle (GT), making these tissues a target of estrogenic EDCs. While estrogenic EDCs are known to impact human development, their precise impacts have been difficult to determine due to our exposure to a broad range of EDCs [2] .
Diethylstilbestrol (DES) is a model chemical for defining the effects of an estrogenic EDC on urogenital development. Diethylstilbestrol is an estrogen receptor agonist and is known to impact reproductive development in the same way in both humans and mice [4] . Diethylstilbestrol was prescribed to pregnant women between 1938 and 1975 to prevent miscarriage or premature birth [5, 6] . Between 5 and 10 million women were prescribed DES in the USA alone [7] , and the drug was also widely used throughout Europe, Australia, and the UK. Not only was DES ineffective in preventing miscarriage, but it caused an increased incidence of reproductive tract cancers in the treated women and in their offspring [8, 9] . As a result, DES was banned in the USA in 1971 and Europe in 1978 [9] . In addition to increasing cancer risk, exposure of the developing fetus to DES also resulted in several developmental abnormalities of the urogenital system, including increased rates of hypospadias [5, 6, 10] .
Hypospadias in boys is characterized by the ectopic placement of the urethra on the ventral aspect of the penis and is associated with reduced fertility, reproductive cancers, and psychological impacts in adulthood [11] . Hypospadias is one of the most common birth defects in humans affecting approximately 1:125 live male births and requires surgical correction between 6 and 24 months of age [12] . The severity of hypospadias is determined by the location of the urethral opening, which can be toward the distal aspect of the glans (mild), on the penis shaft (intermediate) or at the base of the penis or base of the scrotum (severe). Mild hypospadias accounts for approximately 70% of all cases, and is also the most common phenotype reported in DES exposed sons [13] . Estrogen exposures in utero cause reduced anogenital distance (AGD) in both humans and mice, making AGD a reliable proxy for altered hormonal signaling in utero [14, 15] . However, it is still unclear if reduced AGD is correlated with hypospadias.
The incidence of hypospadias has doubled in recent decades in developed countries [10, 16] , and is still increasing [17] . This marked increase is too rapid to be attributed to genetic mutations and, therefore, must result from environmental causes. Taken together, these data suggest that aberrant estrogen signaling, such as that caused by endocrine disruptors, plays a major role in the formation of hypospadias. In mice, in utero exposure to DES is known to cause hypospadias, as it does in humans [18, 19] . DES exposure in utero can also induce hypospadias in developing female mice [19] [20] [21] , resulting in a more proximal urethral opening [22] . Female hypospadias is rare in humans and often left undiagnosed until adulthood [23] . However, female hypospadias is thought to be the cause of other, more common gynecological issues that affect the tissues surrounding the urethra and vagina. A more severe condition involving misplacement of the urethral opening is urethral-vaginal fistula, defined by the joining of the urethral and vaginal canals [24] . This develops in mice exposed to DES prenatally [19] or postnatally [21] , demonstrating that exogenous estrogen signaling is also detrimental to the patterning of the female urogenital system. Knowledge surrounding the detrimental effects of DES on female urogenital development is sorely lacking, despite many adverse health effects in the women exposed in utero [25] .
Current mouse studies investigating the effects of estrogenic endocrine disruptors lack a quantitative method for scoring the mild hypospadias phenotypes that are the most common and clinically relevant phenotypes in humans. Furthermore, they have not examined the effects of low level doses of DES administered via water. Although DES is no longer in use, it provides a basis for understanding how potent synthetic estrogen agonists can impact GT development. The levels of endocrine disruptors vary greatly across different environments [26] , as does our understanding of how these chemicals are metabolized and interact with one another. These factors make it difficult to establish directly relevant environmental levels in any model system. However, it is critical that we comprehensively analyze responses to a dose that is known to negatively impact development before examining the effects of lower doses, administered through more environmentally relevant routes such as via the drinking water.
Here we define the link between DES exposure in utero and its effects on urethral placement in male and female mice. To reflect a more realistic exposure, we treated mice throughout the full window of sexual development, including the period of early gonad differentiation and peak androgen output in males [27] . We examined two exposure levels of DES: a high dose delivered subcutaneously, which mirrored the human clinical exposures during pregnancy [9] , and a low dose, administered via the drinking water at levels similar to the environmental levels of other potent estrogens such as EE2 [26] . Notably, this is also considerably lower than the levels of DES examined previously in mice studies and provides a novel assessment of the impacts of a low-dose exposure via ingestion. We have developed a systematic method for the quantification of hypospadias severity in males and females. By doing this, we were able to assess variation in response to DES and accurately quantify the mild hypospadias phenotypes resulting from the different exposures, which are the most common and clinically relevant to human health. We include analyses of the AGD in exposed males and the proximal urethralvaginal morphology of exposed females. The consequences of DES exposure can be applied broadly to other estrogenic endocrine disruptors that are currently in use today. Our results strongly support the link between estrogenic EDC exposures and the recent dramatic increase in the incidence of hypospadias, illustrating these chemicals can be detrimental, even at a low dose via drinking water.
Materials and methods

Animals and diethylstilbestrol treatments
Wild-type C57BL/6 mice were raised in the animal facility of BioSciences 4 at the University of Melbourne. Mice were handled and killed according to the guidelines established by the National Health and Medical Research Council of Australia (2004) and all protocols were approved by The University of Melbourne Animal Experimentation and Ethics Committee. Timed pregnant mice were exposed to DES, every second day, from embryonic day (E) 9.5-19.5, to ensure the treatment occurred throughout the window of sex determination, early gonad development, and GT development. Diethylstilbestrol (obtained from Sigma-Aldrich) was dissolved in 100% ethanol, and then diluted to 40 μg/mL in 1% ethanol in sterile PBS (phosphate buffered saline). We exposed fetuses to one of two doses of DES. The high dose of 100 μg/kg was administered to pregnant females, via subcutaneous injection, using a 27-gauge needle in the scruff of the neck. This dose is similar to that administered to women during commercial use of DES, and has been reported to cause hypospadias in male mice [18] . The low dose of DES was 200 ng/L via drinking water to represent a potential level and mode of exposure likely to be encountered in the environment [26] , and to determine if such a low level could in fact have an effect. DES was renewed every second day in the drinking water throughout the treatment period and mice were exposed constantly. Assuming a mouse's average intake of 5 mL per day [28] and a weight of 20 g, this dose equated to 0.1 μg/kg every second day (or ∼1/1000th of the injection dose), and will be referred to as the low dose. Control pregnant females received a 1% ethanol in PBS solution through either subcutaneous injection or in their water supply to mimic that of the treatment groups. No differences between control groups were observed and are hence forth referred to as one control group. Male and female GTs were collected at day 7 post-partum and fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS at room temperature for 1 h, or at 4
• C overnight. To measure AGD, mice were laid flat on their back at day 7 post-partum and the distance measured from the base of the GT to the center of the anus with a caliper. Histology Paraffin-embedded GTs were serially sectioned at 7 μm and stained with hematoxylin and eosin (Sigma-Aldrich). Sections were counted from the proximal base where the GT separated from the perineum to the distal tip to give a total GT length. The number of sections where the urethra was internalized was also counted. This was then expressed as a percentage of the total GT length and termed percentage of urethral internalization (PUI), providing a measure of the hypospadias phenotype. All phenotypes were considered mild across both treatment groups. We divided the phenotypes observed in our study into three groups: score 0, 1, or 2, according to the PUI (summarized in Figure 1 ). Images were obtained using a Nikon DS-5M-L1 Digital Sight Camera System.
Statistical analysis
Using Shapiro-Wilk tests, it was determined that GT length and AGD data were normally distributed. T-tests were performed to determine any differences between control and treatment groups for AGD and GT length. Mann-Whitney U tests were used to determine any differences between control and treatment groups for PUI. Pearson's correlation coefficient was used to assess the relationship between AGD and PUI. All data are presented as means ± SEM, with significance set as P < 0.05 unless otherwise stated.
Results
DES exposure in utero caused reduced anogenital distance
All DES-treated mice had normal litter sizes with an equal sex ratio (data not shown). The AGD of male pups was significantly reduced following in utero exposure to DES at both concentrations Figure 2 . DES reduced the anogenital distance (AGD) of post-partum day 7 pups. AGD was significantly reduced in males exposed to both DES treatments compared to control males, but remained significantly larger than female control AGD ( * * * indicates P < 0.001). Epispadias was observed in one male exposed to DES, where the urethra opened on the dorsal aspect of the GT (black arrow) compared to the ventral aspect, as in the control (urethral opening indicated by an asterisk). Scale bar = 300 μm.
compared with control male pups (100 μg/kg: P < 0.001; 0.1 μg/kg: P < 0.001; Figure 2 ). However, male AGD in both treated groups still remained significantly larger than in female control pups (100 μg/kg: P < 0.001; 0.1 μg/kg: P < 0.001; Figure 2 ).
DES exposure caused hypospadias in males
Hypospadias was induced in both DES 100 and 0.1 μg/kg treatments ( Figure 3 ). All phenotypes were glandular and mild across both treatments. There was a significant reduction in PUI for both treatments (100 μg/kg: P = 0.0012; 0.1 μg/kg: P = 0.002; Figure 3B ) compared with the controls. The urethral opening also appeared wider in DES-treated males, further demonstrating a urethral abnormality ( Figure 3A) . Overall, 85% of the males exposed to DES had mild hypospadias. Within this, there was a higher proportion of score 1 hypospadias (53%) in the highest dose of DES, compared to 31% of males with score 2 hypospadias (Table 1) . One case of epispadias was also observed in the high-dose group, where the urethra opened on the dorsal side of the GT ( Figure 3C ). In the low dose, 40% of pups had score 1 hypospadias and 47% had score 2 hypospadias. A small percentage of GTs with score 0 were observed in both DES exposed groups (16% in high dose, 13% in low dose). The PUI for the control and high dose of DES was not correlated with AGD ( Figure 4 ; control, R 2 = 0.029; DES 100 μg/kg R 2 = -0.003). Total GT length was significantly decreased in high-dose DES-treated males (P = 0.037; Figure 5 ), but not in the low-dose DES-treated males.
DES affected female genital tubercle development
Female hypospadias was observed at both doses of DES; however, it occurred more frequently at the high dose ( Figure 6 ; Table 2 ) when compared to control females. The PUI was significantly reduced for the high dose of DES (P = 0.007), but not for the low dose (P = 0.28) when compared to the control group ( Figure 6B ). Similar to the males, 16% of females had score 0 phenotypes in the high-dose group (Table 2) . However, almost half of the females exposed to the high dose exhibited score 2 hypospadias. Some individual females exposed to the high dose had obvious phenotypes at post-partum day 0 (P0), with a defined cleft in one, and an opening at the proximal base of the GT in the other ( Figure 6C ). In females exposed to the low dose, we observed score 0 in 67% of the females. Furthermore, no females in this group had score 2 phenotypes, and all cases observed were score 1. Examination of the most proximal section of the GT revealed a small number of females exposed to 100 μg/kg of DES exhibited urethral-vaginal fistula, and this was not present in the 0.1 μg/kg group ( Figure 7) . These females had a common urethral and vaginal canal ( Figure 7C and D), which were completely separate in control and low-dose DES females ( Figure 7A and B) . In addition, the urethral epithelium appeared to be completely absent in two females, including one with urethral-vaginal fistula ( Figure 7D ).
Discussion
Exogenous estrogen exposure during in utero development, such as that caused by EDCs, has been linked to the increasing incidence of DSDs, including hypospadias. However, direct causality is difficult to define in humans, due to combined exposures to numerous EDCs at unknown concentrations, as well as our variable response to such chemicals. Mouse studies using controlled exposures to EDCs throughout key stages of development, followed by comprehensive analysis of GT defects, are essential to understand this link. We exposed mice in utero to the estrogenic EDC, DES, throughout early reproductive development. DES disrupted GT development causing hypospadias in both males and females, as well as reduced AGD in males, and urethral-vaginal fistula in females. Strikingly, the effect of DES on males was just as severe at a low dose of 0.1 μg/kg, administered via drinking water, as it was at a high dose of 100 μg/kg administered via subcutaneous injection. The reduced AGD observed in DES exposed male mice indicated that altered hormonal signaling was occurring during gestation. We exposed the mice from embryonic day 9.5 to disrupt not only GT differentiation but also gonad differentiation. The output of androgens from the gonad is integral for early male urogenital development and is suppressed by exogenous estrogen exposures [29] , providing a potential reason as to why males are more affected by exogenous estrogen than females. AGD was not correlated with the severity of hypospadias, suggesting hypospadias was not primarily caused by a reduction in androgen signaling. We suggest that DES-induced hypospadias is the combined result of decreased androgen output from the developing testis and increased estrogen signaling directly through endogenous estrogen receptors throughout the developing GT ( Figure 8 ) [30] . Interestingly, a negative correlation between AGD and hypospadias score has been reported in a study examining the effects of an anti-androgen [31] . It is possible because there was no added effect of direct estrogen signaling on the GT. These findings illustrate how integral the balance of estrogens and androgens is for normal GT development and urethral closure in males.
Hypospadias was recorded in males at a frequency (87% in the low and 84% in the high DES groups) comparable with previous studies [19] . Our study used a prolonged DES exposure regimen throughout the window of sex determination and the initial androgen surge from the developing testis, as well as during urethral closure. This encompasses a broad developmental window and reflects a more realistic EDC exposure, which would occur throughout pregnancy. EDCs are present at low levels in the environment, and we have found that EDC delivery via drinking water, at a low dose, induced a high incidence of hypospadias and greater number of more severe phenotypes than the high dose. This was particularly surprising as it was 1/1000th of our high dose and 1/50th of the low dose used in previous studies [19] . These results strongly demonstrate that low-dose estrogen, via ingestion, is sufficient to cause profound effects on male urogenital development.
In the high dose of DES, we also observed one case of epispadias out of a total 19 male pups. Epispadias is a rare disorder in humans [32] , and this is the first time it has been linked to estrogen exposure. This suggests we may observe an increase in this urethral defect in humans exposed to estrogenic EDCs. We observed a variable response to DES treatment within litters, despite using an isogenic line. Intrauterine position (IUP) can impact hormonal signaling in the embryo and is known to have subtle effects on AGD in mice [33] . Some of the males less affected by DES exposure may have been situated next to other males in the uterus, increasing their local exposure to androgens, and perhaps counteracting some of the effects of DES. Since the pups were examined a week after birth, it was not possible to record IUP.
A mouse hypospadias score system was recently developed to measure hypospadias severity following exposure to the antiandrogen, vinclozolin [31] . This mirrors the system used to classify human hypospadias severity, Hypospadias Objective Penile Evaluation (HOPE), which examines morphological characteristics to generate a severity score [34] . In the mouse, hypospadias scores were confirmed against the histologically measured urethral length [31] . In the present study, the high dose of DES caused a significant reduction in overall GT length, and we observed large variation in GT length among all treatment groups. Hence, our method of measuring hypospadias is normalized to the overall GT length and expressed as PUI score. This is particularly important when treating with chemicals that interfere with androgen signaling, which is essential for GT outgrowth, as well as controlling any changes caused by the dehydration and processing of tissues prior to histological analyses. Our refined methodology controls these differences to give a more accurate assessment of hypospadias in our system.
Using our novel quantification method, we also observed a high frequency of hypospadias in females exposed to the highest dose of DES. Early female reproductive tract development usually occurs in the absence of hormonal signaling [35, 36] . DES exposure leads to the ectopic activation of ERs throughout the female reproductive tract at a much earlier time point than normal, which can disrupt key patterning processes [37] . This is evident with the high incidence of hypospadias observed in females exposed to the highest dose of DES, as well as the disrupted partitioning of the urethral and vaginal canals in some females exhibiting urethral-vaginal fistula. Previous studies [19] reported urethral-vaginal fistula at a frequency of 100% following DES exposure. Our reported frequency is much lower likely because we defined a proximal urethral opening as hypospadias and not fistula. Many females presenting with a proximal urethral opening still had normal urethral and vaginal partitioning, and therefore were not classified as having fistula.
The high dose of DES also appeared to affect development of the urethral epithelium in two of the nineteen females examined. This is in contrast to the typical responses to DES, where the vaginal epithelium proliferates [38] . In fact, these females mirrored a phenotype observed in estrogen receptor α knockout (ERαKO) mice, where reduced estrogen signaling results in a lack of a defined urethral epithelium [39] . While the phenotype only affected 2 out of 19 females, potentially due to IUP effects, it clearly indicates that development of the urethral epithelium is sensitive to estrogen.
Research into the effects of endocrine disruptors on female sexual development is sorely lacking, with the etiology behind female hypospadias and urethral-vaginal fistula virtually unknown. It is clear that aberrant and excessive estrogen signaling from endocrine disruptors, such as DES, in this early window can have profound impacts on early female reproductive development, as observed in the DES daughters. Although DES is no longer in use, it is a model synthetic estrogen that is known to impact human and mouse reproductive development. The consequences of DES exposure can be broadly applied to other potent synthetic estrogens such as the highly prevalent 17-ethinylestradiol (EE2) a component of the combined contraceptive pill. Studies examining DES and EE2 potency suggest that DES and EE2 have similar affinity for ER [40] [41] [42] [43] . However, the potency of both chemicals can change greatly depending on the target organ and route of exposure [44] . We have defined regimens for generating mild hypospadias and for consistently measuring the phenotype in the mouse model. This is an important advance in developing clinically relevant animal models of environmentally induced mild human hypospadias. Our methodology of hypospadias quantification and treatment regimen can be Table 2 . Frequency of hypospadias and urethral-vaginal fistula in day 7 post-partum female mice.
Hypospadias severity
Control (n = 3) DES 100 μg/kg (n = 19) DES 0.1 μg/kg (n = 9) Score 0 100% 16% 67% Score 1 0% 37% 33% Score 2 0% 47% 0% Urethral-vaginal fistula 0% 11% 0% Figure 7 . DES affected proximal genital development in females. Transverse sections of control females (A) shows a distinct separation between the urethra (u) and vagina (v), as well as a urethral epithelium (ue; arrow). Females exposed to 0.1 μg/kg of DES had the same morphology as control females. Some females exposed to 100 μg/kg of DES (C, D) had urethral-vaginal fistula (uvf), showing a clear joining of the urethral and vaginal canals. There also appeared to be a lack of epithelium around the urethra (D, arrowhead). Scale bar = 300 μm. Figure 8 . DES may have both indirect and direct effects on the genital tubercle (GT) to cause hypospadias. Decreased androgen output from the testis can result in reduced anogenital distance (AGD), and in decreased androgen signaling in the GT, causing hypospadias. DES may also act directly to activate estrogen receptors in the GT, contributing to the hypospadias phenotype.
applied to accurately examine the impact of any potential EDC on urethral patterning. We show that very low doses of DES, administered via drinking water, are just as detrimental to male GT development as high doses.This study presents a framework for investigations into the molecular and developmental mechanisms affected by EDCs in the development of this common disease. Furthermore, we have shown that estrogenic EDC can have a profound impact on female GT development. This area of research is poorly lacking in mice and humans, and these findings indicate the need for further investigation into the impacts of EDCs on female reproductive development.
